Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01038466
Registration number
NCT01038466
Ethics application status
Date submitted
10/09/2009
Date registered
24/12/2009
Date last updated
24/12/2009
Titles & IDs
Public title
Observation Only Study Involving Participants Enrolled in the CHAT Trial
Query!
Scientific title
Follow-Up Observational Study In CHAT Trial Participants With Advanced And/Or Metastatic Breast Cancers That Overexpress HER2, Who Were Randomised To Receive Trastuzumab And Docetaxel With Or Without Capecitabine
Query!
Secondary ID [1]
0
0
CB.0901
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
CHAT trial participants - CHAT trial participants whose data was used in the final data analysis for the CHAT study
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The primary endpoints are Time-to-Progression and Overall Survival in the two treatment arms of the CHAT study.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
survival
Query!
Secondary outcome [1]
0
0
Progression-Free-Survival
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
7 years
Query!
Secondary outcome [2]
0
0
Overall Survival
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
7 years
Query!
Secondary outcome [3]
0
0
Anatomical sites of progression
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
7 years
Query!
Eligibility
Key inclusion criteria
- CHAT trial participants whose data was used in the final data analysis for the CHAT
study
Query!
Minimum age
No limit
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Any patients who have withdrawn consent to the CHAT study
Query!
Study design
Purpose
Query!
Duration
Query!
Selection
Query!
Timing
Retrospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Unknown status
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/11/2009
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
222
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
CONTACT Asia Pacific - Geelong
Query!
Recruitment postcode(s) [1]
0
0
3220 - Geelong
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Contact Asia Pacific
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The aim of the CHAT study ("An open-label, randomized Phase II study of Herceptin
(trastuzumab), Taxotere® (docetaxel) and Xeloda (capecitabine) in combination, versus
Herceptin (trastuzumab) plus Taxotere® (docetaxel), in patients with advanced and/or
metastatic breast cancers that overexpress HER2") was to test the combination of Trastuzumab
and Docetaxel with or without capecitabine as first-line therapy for HER2 positive locally
advanced or metastatic breast cancer.
Overall Response Rate was the primary endpoint of the CHAT study. This study failed to meet
its primary objective of showing a difference between the treatment groups, with equivalent
high response rates for the Trastuzumab plus Docetaxel and Trastuzumab, Docetaxel plus
capecitabine arms.
Secondary endpoints in the CHAT study were Progression-Free-Survival, Time-to-Progression,
Overall Survival, duration of response and safety profile. Whilst analysis of the existing
data is consistent with improvement with the triplet therapy, interpretation is compromised
by the relatively short median follow-up of 24 months. In hindsight the statistical design
was flawed by selection of a sub optimal primary endpoint and consequently data was collected
and analysed early in relation to time-dependent endpoints. Beyond CHAT will permit capture
of mature data for time-related endpoints. Time-to-Progression and Overall Survival are the
co-primary endpoints for the Beyond CHAT protocol. The impact of treatment following the
first progression, on survival, will be explored.
Time-to-Progression will be defined from the time interval between the date of randomisation
and the occurrence of progressive disease under therapy according to RECIST criteria.
Overall Survival will be defined as the time from date of randomisation to date of death
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01038466
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Richard Bell, MBBS
Query!
Address
0
0
Contact Asia Pacific
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01038466
Download to PDF